Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.

ABSTRACT:

Background

The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) versus ASC alone in aESCC.

Methods

We conducted a tri-center retrospective cohort study (n = 166) including patients with aESCC who had experienced disease progression on palliative first-line therapy. A propensity score model using inverse probability of treatment weighting (IPTW) was implemented for comparative efficacy analysis of overall survival (OS) in patients with second-line + ASC (n = 92, 55%) versus ASC alone (n = 74, 45%).

Results

The most frequent second-line regimens used were

SUBMITTER: Muller M 

PROVIDER: S-EPMC8488508 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature